Needham analyst David Saxon raised the firm’s price target on SI-Bone (SIBN) to $27 from $24 and keeps a Buy rating on the shares. The firm has also added the stock to its ‘Conviction List’, replacing Alcon (ALC) and named it Needham’s ‘2026 Top Pick’. Needham believes that SI-Bone can deliver potential upside to estimates over the near-term, which should drop through to drive increasing profitability. The firm further notes that the company’s upcoming product launches could result in active surgeon adoption across its portfolio to drive utilization higher.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SIBN:
- SI-Bone price target raised to $23 from $20 at Morgan Stanley
- SI-BONE, Inc. Reports Strong Q3 2025 Earnings
- SI-Bone’s Strong Q3 Performance and Strategic Initiatives Signal Promising Growth and Compelling Buy Opportunity
- SI-Bone’s Strong Financial Performance and Growth Prospects Justify Buy Rating
- SI-Bone’s Strong Financial Performance and Optimistic Future: Buy Rating Affirmed by David Saxon